BRCA2 and ovarian cancer: These 36 variants were selected because they occur in individuals from families with breast or ovarian cancer in which no other deleterious mutation in BRCA1 or BRCA2 was found and were functionally tested under the same protocols and conditions, yielding standardized measurements of each variant's transactivation activity with respect to wild-type.